Tocilizumab shortage continues as pandemic wears on
August 19, 2021
Emergency use authorization of tocilizumab for COVID-19 has led to a global shortage, but supplies for rheumatoid arthritis and other inflammatory conditions are faring better – for now.
COVID-19’s impact on lupus inpatients examined in study
March 24, 2021
Younger inpatients with COVID-19 and SLE showed higher mortality than did COVID-19 inpatients of similar age from the general population in a French epidemiologic study.
Rheumatologic disease activity an important influencer of COVID-19 death risk
February 5, 2021
COVID-19 Global Rheumatology Alliance physician registry data highlight need to maintain adequate disease control to lower risk for death from COVID-19.
COVID-19 risks in rheumatic disease remain unclear
November 7, 2020
Elevated COVID-19-related risks, many associated with comorbidities, emerged in a match-control study, whereas a systematic review delivers more encouraging news for people living with rheumatic disease.
COVID-19–related HCQ shortages affected rheumatology patients worldwide
November 6, 2020
Data from the Global Rheumatology Alliance Patient Experience Survey presented at ACR Convergence 2020 demonstrate that the severity of shortages differed widely across the globe.
Even a few days of steroids may be risky, new study suggests
July 9, 2020
A retrospective study of more than 2.6 million Taiwanese adults echoes findings from a 2017 cohort study of more than 1.5 million U.S. adults.
ACIP approves flu vaccine recommendations for 2020-2021
June 25, 2020
Next season’s vaccination options include new high-dose quadrivalent vaccines for seniors.
EULAR’s COVID-19 recommendations offer no surprises
June 11, 2020
The provisional recommendations cover four themes: general measures and preventing SARS-CoV-2 infection, managing patients without COVID-19 and those with the infection, and preventing COVID-19 lookalikes.
Age leads COVID-19 hospitalization risk factors in RMDs
June 10, 2020
Glucocorticoid use, cardiovascular comorbidity, and male gender were also found to increase the risk of hospitalization from COVID-19 in inflammatory rheumatic diseases.
Most rheumatology drugs don’t increase COVID-19 hospitalization risk
June 4, 2020
“These results provide, for the first time, information about the outcome of COVID-19 in patients with rheumatic and musculoskeletal diseases.”